domingo, 15 de noviembre de 2026
BuscarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· May 19, 2026

How Investors Are Reacting To Salesforce (CRM) After Bank of America Flags AI Monetization Challenges

View original at finance.yahoo.com
“Salesforce's narrative projects $51.9 billion revenue and $10.3 billion earnings by 2028.”
Verbatim excerpt from the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Salesforce faces a structural reset as AI reshapes its core CRM and agentic offerings.

    60% confidence
  • The near-term focus for Salesforce is squarely on whether AI features can be priced and adopted fast enough to offset slowing CRM growth.

    60% confidence
  • Salesforce's earnings need to grow approximately $3.6 billion from the current $6.7 billion to reach the 2028 target of $10.3 billion.

    60% confidence
  • Salesforce's AI monetization must not erode the existing seat-based CRM model; convincing investors on this is the biggest near-term swing factor.

    60% confidence
  • The most optimistic analysts project Salesforce revenues near $58.9 billion and earnings around $11.6 billion by 2029, expecting AI-driven workflows to lock customers in more tightly.

    60% confidence
  • Salesforce may be shifting from a high-growth story to a mature cash generator.

    60% confidence
  • Salesforce's consensus forecasts imply a fair value of $317.21, representing 77% upside to its current market price.

    60% confidence
  • Salesforce's narrative projects $51.9 billion in revenue and $10.3 billion in earnings by 2028, requiring 9.6% annual revenue growth.

    60% confidence

Data points we hold from this source

Salesforce · net income6.7 USD
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Late-2026 Biotech Catalyst Season: FDA Decisions and Pivotal Readouts Converge Across Oncology, Hepatology and Cardiometabolic
Mid-November 2026 is dense with scheduled biotech catalysts. The ivonescimab BLA PDUFA date is 2026-11-14, the lorundrostat PDUFA date is 2026-12-22, and Phase 3 ECLIPSE hepatitis delta data are due in Q1 2027. Alongside these, siRNA and antibody programs (plozasiran, elebsiran/tobevibart, ianalumab, nipocalimab) reported or presented data at AHA, AASLD, ACR and ASH, while Oryzon advanced iadademstat in AML with Spanish trial authorizations and a planned ALICE-3 Phase III. Late-stage data and regulatory milestones are driving the sentiment. A planned delisting (EGM 2026-11-19, application 2027-01-25) is a separate corporate-structure event with no clear link to the rest.
Nuestra lectura de los datos ›
Señales que seguimos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patrones que observamos ›
Donde las fuentes discrepan
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,995
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,995 hechos verificados con la fuente5,580 documentos fuente archivados
Consulta estos datos → isubstrate.com
How Investors Are Reacting To Salesforce (CRM) After Bank of America Flags AI Monetization Challenges — Source | Via News | es.via.news